Incyte Genomics Inc
Market cap $23.5B
$117.67
INCY
$117.67
+0.84% today
Buy with €1M virtual cash · No real money
Incyte Genomics Inc (INCY) is a publicly traded company listed on the XNAS. As of July 27, 2026, Invest's signal rates INCY a Buy, with the stock up 66% over the past year. You can practice trading INCY risk-free with €1,000,000 in virtual cash.
Key stats
As of July 27, 2026
Market Cap
$23.5B
Volume
1.2M
52-wk High
$119.60
52-wk Low
$69.70
Day High
$119.13
Day Low
$116.70
P/E (TTM)
18.33
Revenue (TTM)
$4.9B
EPS (TTM)
$6.42
Performance
1M
+8.5%
6M
+12.0%
1Y
+66.5%
Invest signal · INCY
BuyAlgorithmic signal from price trend, valuation, and fundamentals — educational only, not financial advice.
INCY overview
AI overviewRevenue & EPS — last 8 quarters
QoQ rev -6.8%Revenue
$1BEPS (diluted)
$1.47 per shareLatest INCY news
Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster Potential
Benzinga · Jun 9
China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication
GlobeNewswire Inc. · Sep 28
Liposarcoma Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 15+ Companies and 20+ Therapies | DelveInsight
GlobeNewswire Inc. · May 27
Merus annonce ses résultats financiers pour le premier trimestre 2025 et fait le point sur ses activités
GlobeNewswire Inc. · May 9
Generic Oncology Drugs Market Size Estimated to Reach USD 30,998 Mn by 2034, Rising Global Cancer Cases Increase Demand for Affordable Treatments
GlobeNewswire Inc. · May 7
About Incyte Genomics Inc
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma).
The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
Employees
2,844
30-Day Win Rate · INCY
15 days
8 days
Last 23 sessions
How to practice trading INCY
- 1
Use the INCY buy panel above
Set a quantity and hit Buy at the real market price — right here, nothing to download.
- 2
Trade with €1,000,000 virtual cash
You get a million in virtual money instantly to invest, risk-free.
- 3
Create a free account to save it
Sign up in seconds to keep your portfolio and track its performance.
- 4
Track and compete
Watch your portfolio grow and climb the global leaderboard — or start a private league.
- 5
Prefer mobile? Get the iOS app
Invest is also free on the App Store, synced with your web account.
Top INCY traders on Invest
Full leaderboardFrequently asked questions
Is INCY a good stock to buy right now?
As of July 27, 2026, Invest's signal rates INCY a Buy, based on its price trend, valuation, and fundamentals (P/E around 18.3), with the stock up 66% over the past year. This is an educational signal, not financial advice — the best way to test the thesis is to practice trading INCY risk-free first.
What is Incyte Genomics Inc's (INCY) market cap?
Incyte Genomics Inc has a market capitalization of approximately $23.5B, on trailing-twelve-month revenue of about $4.9B.
How has INCY stock performed?
INCY is up 66% over the past year and up 12% over six months. Its 52-week range runs roughly from $69.70 to $119.60. Past performance doesn't predict future results.
How can I practice trading INCY for free?
On Invest you get €1,000,000 in virtual cash and can buy INCY at real market prices right in your browser — no download and no real money at risk. Create a free account to save your portfolio and track its performance over time.
More stocks to practice
Designs the iPhone, Mac, and a huge services ecosystem.
Windows, Office, Azure cloud, and enterprise software.
The leading designer of AI and gaming GPUs.
E-commerce giant and the largest cloud provider (AWS).
Google Search, YouTube, Android, and cloud.
Facebook, Instagram, WhatsApp, and the metaverse.
Compare INCY with peers